Results to Be Presented at ACG 2026
Met Primary and Secondary Endpoints

HK inno.N's new drug K-CAB (ingredient: tegoprazan) for gastroesophageal reflux disease significantly improved heartburn and acid reflux symptoms in a U.S. Phase 3 clinical trial. After confirming its therapeutic effects in non-erosive gastroesophageal reflux disease, following erosive esophagitis, expectations for approval by the U.S. Food and Drug Administration (FDA) are also rising.

Product image of K-CAB, HK inno.N's new drug for gastroesophageal reflux disease. HK inno.N.

Product image of K-CAB, HK inno.N's new drug for gastroesophageal reflux disease. HK inno.N.

View original image

On October 12, HK inno.N said its U.S. partner, Sebela Pharmaceuticals, would present the Phase 3 results for K-CAB in non-erosive gastroesophageal reflux disease (NERD) at the annual meeting of the American College of Gastroenterology (ACG 2026), being held in Tennessee. The results are scheduled to be presented on October 14 local time by Professor Ronnie Fass of Case Western Reserve University School of Medicine.


The trial was conducted in 783 U.S. adult patients. Patients received tegoprazan 50 mg, tegoprazan 100 mg, or a placebo once daily for four weeks, and the treatment effects were compared. The durability of the effects was then evaluated in a 20-week extension study.


According to the trial results, both doses of tegoprazan met the primary and secondary endpoints. Through Week 4, the percentage of days without heartburn over a 24-hour period was 17.3% in the placebo group, compared with 26.2% in the tegoprazan 50 mg group and 30.1% in the 100 mg group. The percentage of days without nighttime heartburn was also significantly higher, at 36.1% in the 50 mg group and 39.9% in the 100 mg group, versus 27.0% in the placebo group.


The percentage of days without either acid reflux or heartburn also improved. On a composite measure assessing both symptoms, the tegoprazan 50 mg group showed a 60% relative improvement over the placebo group, while the 100 mg group showed a 76% relative improvement. The improvement in heartburn was maintained in the 20-week extension study.


HK inno.N plans to accelerate its entry into the U.S. market based on the trial results. In January 2026, Sebela Pharmaceuticals submitted a New Drug Application (NDA) for tegoprazan to the FDA. K-CAB has signed technology transfer or finished-product export agreements in 55 overseas countries and has been approved in 24 countries, including South Korea, and launched in 22 countries.



A HK inno.N official said, "This presentation is significant because it shares the clinical value of K-CAB, demonstrated in a large number of U.S. patients, at an international academic conference. We will work closely with our partner to strengthen K-CAB's position in the U.S. market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing